A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension
I. To determine which drug has the greatest effect on Ang-(1-7) levels in cancer patients
I. To determine the effect of these drugs on levels of Ang II, VEGF, PlGF, and ACE in the
OUTLINE: Patients are randomized to 1 of 4 treatment arms.
- ARM I: Patients receive oral benazepril hydrochloride once daily on days 1-7.
- ARM II: Patients receive oral lisinopril once daily on days 1-7.
- ARM III: Patients receive oral ramipril twice daily on days 1-7.
- ARM IV: Patients receive oral losartan potassium once daily on days 1-7. In all arms,
treatment continues in the absence of unacceptable toxicity.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Changes in Ang1-7 levels are significantly different among patients after ACE-I/ARB treatment
7 days post-baseline
Wake Forest University
United States: Institutional Review Board
|Wake Forest University Health Sciences||Winston-Salem, North Carolina 27157|